Latest Intelligence on Pharmaceuticals and Healthcare

Published within

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

ADHD: FDA debates black box warnings

In a controversial move, an FDA panel has recommended against ADHD drugs bearing "black box" warnings about psychiatric and cardiovascular risks in children. While the regulator's final decision will be eagerly awaited by both patients and drug makers alike it looks like Eli Lilly's Strattera will remain standing strong whatever the ruling.

Published By Datamonitor
24 Mar 2006
ResearchWire
ResearchWire

ADHD: immature adult market continues to offer greatest commercial potential

Published By Datamonitor
14 May 2008
CommentWire
CommentWire

ADHD: NICE ruling for Ritalin, but will it boost sales?

Published By Datamonitor
02 Nov 2000
ResearchWire
ResearchWire

ADHD: stimulants set for a depression in sales

Published By Datamonitor
18 Aug 2005
Expert View
Expert View

Adjuvant therapy offers hope against deadly cancer

Non small cell lung cancer (NSCLC) is the most common form of lung cancer in the world, afflicting more than 330,000 new patients in the seven major pharmaceutical markets every year. However, according to a new report from Datamonitor, new trials have confirmed the effectiveness of adjuvant therapy, which is expected to rapidly become the standard therapy for NSCLC.

Published By Datamonitor
03 Dec 2004
CommentWire
CommentWire

Adolor: no pain, large gains

Published By Datamonitor
21 Dec 2000
Expert View
Expert View

Adult acute leukemia: demand for innovative drugs that prolong survival

A new report estimates that there will be approximately 84,000 cases of adult and childhood leukemia in the world's seven major pharmaceutical markets in 2006. Acute leukemias will account for 43% of these cases, and, although this market is relatively small compared to other cancer types, the clear unmet needs and regulatory incentives should help encourage drug makers.

Published By Datamonitor
11 May 2006
Expert View
Expert View

Advair: GlaxoSmithKline to lead the asthma market

New research from Datamonitor has suggested that the asthma/COPD market will enjoy a 35% increase and reach a value of over $18 billion by 2011. This growth will be largely driven by the success of drug delivery technology, rather than novel drug launches. GlaxoSmithKline should therefore be the main beneficiary of this market expansion although its rivals are looking to close the gap.

Published By Datamonitor
24 Oct 2003
CommentWire
CommentWire

Advanced Life Sciences: aiming for second place with cethromycin

Considering the strong launch of the only ketolide currently available, Sanofi-Aventis' Ketek, Advanced Life Sciences' antibiotic cethromycin is expected to perform well in its first few years on the market, once approved. Indeed, with off-label use, cethromycin revenues could reach $145 million by 2010, beating Wall Street consensus of $123 million. However, Ketek will remain a formidable rival.

Published By Datamonitor
14 Jun 2006
ResearchWire
ResearchWire

Advanced Life Sciences: aiming for second place with cethromycin

Published By Datamonitor
30 Jun 2006

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

No help is available.